These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10854136)

  • 1. Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer.
    Hilger RA; Jacek G; Oberhoff C; Kredtke S; Baumgart J; Seeber S; Scheulen ME
    Cancer Chemother Pharmacol; 2000; 45(6):483-8. PubMed ID: 10854136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors.
    Hilger RA; Harstrick A; Eberhardt W; Oberhoff C; Skorzec M; Baumgart J; Seeber S; Scheulen ME
    Cancer Chemother Pharmacol; 1998; 42(2):99-104. PubMed ID: 9654108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.
    Główka FK; Karaźniewicz-Łada M; Grund G; Wróbel T; Wachowiak J
    Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S67-70. PubMed ID: 18978748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity.
    Meden H; Wittkop Y; Kuhn W
    Anticancer Res; 1997; 17(3C):2221-3. PubMed ID: 9216692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.
    Galaup A; Paci A
    Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):333-47. PubMed ID: 23157726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation.
    Ten Brink MH; Ackaert O; Zwaveling J; Bredius RG; Smiers FJ; den Hartigh J; Lankester AC; Guchelaar HJ
    Ther Drug Monit; 2014 Aug; 36(4):465-72. PubMed ID: 24487253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).
    Sehouli J; Tomè O; Dimitrova D; Camara O; Runnebaum IB; Tessen HW; Rautenberg B; Chekerov R; Muallem MZ; Lux MP; Trarbach T; Gitsch G
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):541-550. PubMed ID: 27896440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation.
    Bojko P; Hilger RA; Ruehm SG; Dirsch O; Seeber S; Scheulen ME
    Bone Marrow Transplant; 2003 Mar; 31(6):487-91. PubMed ID: 12665845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.
    Scheulen ME; Hilger RA; Oberhoff C; Casper J; Freund M; Josten KM; Bornhäuser M; Ehninger G; Berdel WE; Baumgart J; Harstrick A; Bojko P; Wolf HH; Schindler AE; Seeber S
    Clin Cancer Res; 2000 Nov; 6(11):4209-16. PubMed ID: 11106234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study.
    Chekerov R; Kaltenecker G; Reichert D; Göhler T; Klare P; Oskay-Özcelik G; Sauer U; Wischnik A; Vehling-Kaiser U; Becker M; Hutzschenreuter U; Ammon A; Heidrich-Lorsbach E; Sehouli J
    Anticancer Res; 2015 Dec; 35(12):6869-75. PubMed ID: 26637909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation.
    Główka FK; Łada MK; Grund G; Wachowiak J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 May; 850(1-2):569-74. PubMed ID: 17210272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
    Spieth K; Kaufmann R; Gille J
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):377-82. PubMed ID: 12879280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study. The Danish Ovarian Cancer Study Group.
    Keldsen N; Madsen EL; Havsteen H; Kamby C; Laursen L; Sandberg E
    Gynecol Oncol; 1998 May; 69(2):100-2. PubMed ID: 9625618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL).
    Fichtner I; Becker M; Baumgart J
    Eur J Cancer; 2003 Apr; 39(6):801-7. PubMed ID: 12651206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG).
    Reed NS; Poole CJ; Coleman R; Parkin D; Graham JD; Kaye SB; Ostrowski J; Duncan I; Paul J; Hay A;
    Eur J Cancer; 2006 Jan; 42(2):179-85. PubMed ID: 16337372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a High Pressure Liquid Chromatography-UV Method for the Determination of Treosulfan and Its Epoxy Metabolites in Human Plasma and Its Application in Pharmacokinetic Studies.
    Koyyalamudi SR; Kuzhiumparambil U; Nath CE; Byrne JA; Fraser CJ; O'Brien TA; Earl JW; Shaw PJ
    J Chromatogr Sci; 2016 Mar; 54(3):326-33. PubMed ID: 26433392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro.
    Köpf-Maier P
    In Vivo; 1998; 12(3):275-88. PubMed ID: 9706471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treosulfan in the treatment of metastatic renal cell carcinoma.
    Rigos D; Wechsel HW; Bichler KH
    Anticancer Res; 1999; 19(2C):1549-52. PubMed ID: 10365143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of active secondary progressive multiple sclerosis with treosulfan.
    Wiendl H; Kieseier BC; Weissert R; Mylius HA; Pichlmeier U; Hartung HP; Melms A; Kuker W; Weller M
    J Neurol; 2007 Jul; 254(7):884-9. PubMed ID: 17446994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.